People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2017 |
| Sofregen Medical Inc. | — | Biotechnology | Series A | $17.8M | $293.0M | 2016 |
Milan Kofol at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Milan Kofol on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| HOWARD WEISMAN | 2 | 3 |
| Robert Langer | 1 | 36 |
| Amir Nashat | 1 | 14 |
| Alan Crane | 1 | 9 |
| Harry Wilcox | 1 | 6 |
| Doug Cole | 1 | 6 |
| NEIL EXTER | 1 | 5 |
| PETER HUTT | 1 | 4 |
| Timothy Richards | 1 | 4 |
| R. ROX ANDERSON | 1 | 3 |
| DOUG LEVINSON | 1 | 2 |
| AMY SIEGEL | 1 | 2 |
| Stuart Blitz | 1 | 2 |
| Anh Hoang-Lindsay | 1 | 2 |
| HOWARD BERNSTEIN | 1 | 2 |
| DONALD HARDISON | 1 | 1 |
| MILAN ROX KOFOL | 1 | 1 |
| DONALD ROX HARDISON | 1 | 1 |
| ALAN ROX CRANE | 1 | 1 |
| DOUG ROX COLE | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.